Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
about
Tubulin-interactive natural products as anticancer agentsDiscovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapyRegioselective synthesis of water-soluble monophosphate derivatives of combretastatin A-1.Cell death signaling and anticancer therapyMicrotubule inhibitor, SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells.The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.Structural interrogation of benzosuberene-based inhibitors of tubulin polymerizationDesign, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agentsTumour vascular disrupting agents: combating treatment resistance.Microtubule dynamics as a target in oncology.Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole (OXi8006)Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents.Tumor vasculature as target for therapeutic intervention.Tubulin: an example of targeted chemotherapy.Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation.Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.Synthesis, cytotoxic properties and tubulin polymerization inhibitory activity of novel 2-pyrazoline derivatives.Synthesis and cytotoxic evaluation of N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-arylsulfonamide and N-aryl-(4-methoxy-1H-benzo[d]imidazol)-7-sulfonamide analogs of combretastatin A-4.Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.Biological evaluation of benzosuberones.Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells.Mitosis is not a key target of microtubule agents in patient tumors.
P2860
Q24650163-4390E99F-B3C1-4A48-A732-1EA4D0776BABQ31024172-5E4512B4-DD23-48F4-B3D8-15A9B826085BQ34954063-FAD4FC4C-F2B8-4913-9359-A9E9FB1A88DCQ35556939-4B51923C-32CB-468E-B1DF-6B6DA5D3D74EQ35743971-F81289E1-0853-451F-BE8E-47B808915DF5Q35972102-F687E89B-58DE-4453-A03A-4096F5FCB4E7Q36381403-D1D81744-0680-4353-94E9-D37A818528C7Q36756648-A635B0CB-F7AA-4D13-BBB8-DEC82511A9E4Q36788673-22A6E64B-4FB2-40B1-9A0F-E0CAD8B75088Q36839418-38C338BE-8D28-4418-9503-9CFE41C12A1EQ37280244-4FF0CEF8-A8C9-4860-9ED4-B9B895AC9D8EQ37360708-3D4D4B1A-5C75-4918-8D6A-D96BA740EB91Q37534993-DF1C3117-6DA8-4F93-9BE8-51CFB850036FQ37626788-A30D594E-4605-4568-B843-2D58126FE7C4Q37670789-9BA66506-E9F6-4EE9-AB94-7D15F72EBA8FQ37800110-874B913A-F510-44C6-9461-F88E41DAC9EFQ38086872-E56B5E56-29E1-4D16-8444-EFD25E58D6F7Q38910151-31DA5681-F44E-4B1D-A7AF-E9BD15D87F0FQ39010651-6F1BC4F6-B1B5-42C2-8677-F061A6172216Q39247534-A4A89EDD-47FD-42EA-A8CB-B5AA30A58BAFQ39347168-08445930-FFE0-46CC-BADC-453609E566E5Q39565073-BAE1D042-5C16-4E42-94AD-F8C5B45EBA06Q39620499-091076B5-F863-44A1-B091-C8DBD2361C42Q46533210-E8D75DDB-13E5-447F-A441-6A09FC4CE640Q52663446-4FE91ED6-03FA-4BA0-82D9-C65E6DCB5B97Q53271035-58898CB3-DEDA-4CD0-9A4B-B2DE9EA96DEE
P2860
Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
@en
Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
@nl
type
label
Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
@en
Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
@nl
prefLabel
Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
@en
Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
@nl
P2860
P1476
Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
@en
P2093
Chryso Kanthou
Gillian M Tozer
P2860
P304
P356
10.1517/14728222.11.11.1443
P407
P577
2007-11-01T00:00:00Z